About Serca Pharmaceuticals
Serca Pharmaceuticals is a biopharmaceutical company focusing on development of its lead drug candidate intended for use in a novel treatment of acute myocardial infarction.
Serca Pharmaceuticals (Oslo, Norway) was established in 2018 based on more than 10 years of research at University of Oslo/Oslo University Hospital (OUH) on the signal pathways regulating heart contractility.
Serca Pharmaceuticals’ lead candidate 13-M is a small molecule with the potential to reduce myocardial infarction area in the treatment of acute myocardial infarction by normalizing the cardiac cell calcium (Ca2+) transport via the SERCA2 pump.
The Company initiated collaboration with Cadila Pharmaceuticals (India) for the nonclinical product development and the subsequent clinical Phase 1 and Phase 2 trials. The Company’s strategy is to demonstrate clinical Proof of Concept in Phase 2 followed by further worldwide development and commercialization. The Company will seek to grow organically and through partnering and collaboration with major players in the Field.
